An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer

ConclusionCollectively, our results suggest that the combination of AKT inhibitor and PARP inhibitor could be a viable approach for clinical testing in recurrent ovarian cancer patients.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research